Mirati Therapeutics (MRTX) Shares Up -0.2%
Mirati Therapeutics, Inc. (NASDAQ:MRTX) shot up 0.2% during trading on Wednesday . The stock traded as high as $30.05 and last traded at $29.85. 369,754 shares were traded during mid-day trading, a decline of 24% from the average session volume of 488,073 shares. The stock had previously closed at $29.90.
Several research firms recently commented on MRTX. BidaskClub raised Mirati Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday. ValuEngine cut Mirati Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Zacks Investment Research raised Mirati Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, November 7th. Oppenheimer reaffirmed a “buy” rating and issued a $18.00 price target on shares of Mirati Therapeutics in a report on Wednesday, November 22nd. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $13.00 price target on shares of Mirati Therapeutics in a report on Thursday, October 12th. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Mirati Therapeutics has a consensus rating of “Buy” and a consensus price target of $14.75.
In other Mirati Therapeutics news, major shareholder Venbio Select Advisor Llc acquired 650,000 shares of the stock in a transaction that occurred on Thursday, November 16th. The stock was bought at an average cost of $13.00 per share, for a total transaction of $8,450,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jamie Christensen sold 14,725 shares of the stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $22.99, for a total value of $338,527.75. Following the completion of the transaction, the senior vice president now owns 6,395 shares of the company’s stock, valued at $147,021.05. The disclosure for this sale can be found here. Insiders sold 71,314 shares of company stock valued at $1,831,831 over the last quarter. 5.10% of the stock is currently owned by company insiders.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.